Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy.
Ampuero J, Lucena A, Berenguer M, Hernández-Guerra M, Molina E, Gómez-Camarero J, Valdivia C, Gómez E, Casado M, Álvarez-Navascuez C, Jorquera F, García-Buey L, Díaz-González Á, Morillas R, García-Retortillo M, Sousa JM, Pérez-Medrano I, Simón MÁ, Martínez J, Arenas J, Londoño MC, Olveira A, Fernández-Rodríguez C; ColHai Registry. Ampuero J, et al. Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826. Online ahead of print. Hepatology. 2024. PMID: 38447019
The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity.
Robles-Diaz M, Garcia-Cortes M, Medina-Caliz I, Gonzalez-Jimenez A, Gonzalez-Grande R, Navarro JM, Castiella A, Zapata EM, Romero-Gomez M, Blanco S, Soriano G, Hidalgo R, Ortega-Torres M, Clavijo E, Bermudez-Ruiz PM, Lucena MI, Andrade RJ; Spanish DILI Registry; Faster Evidence-based Translation (SAFE-T) Consortium. Robles-Diaz M, et al. Liver Int. 2015 Nov;35(11):2474-82. doi: 10.1111/liv.12834. Epub 2015 Apr 8. Liver Int. 2015. PMID: 25809419
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Alonso S, Riveiro-Barciela M, Fernandez I, Rincón D, Real Y, Llerena S, Gea F, Olveira A, Fernandez-Carrillo C, Polo B, Carrión JA, Gómez A, Devesa MJ, Baliellas C, Castro Á, Ampuero J, Granados R, Pascasio JM, Rubín A, Salmeron J, Badia E, Planas JM, Lens S, Turnes J, Montero JL, Buti M, Esteban R, Fernández-Rodríguez CM. Alonso S, et al. Among authors: ampuero j. J Viral Hepat. 2017 Apr;24(4):304-311. doi: 10.1111/jvh.12648. Epub 2016 Dec 9. J Viral Hepat. 2017. PMID: 27935168 Free article.
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
Perelló C, Carrión JA, Ruiz-Antorán B, Crespo J, Turnes J, Llaneras J, Lens S, Delgado M, García-Samaniego J, García-Paredes F, Fernández I, Morillas RM, Rincón D, Porres JC, Prieto M, Lázaro Ríos M, Fernández-Rodríguez C, Hermo JA, Rodríguez M, Herrero JI, Ruiz P, Fernández JR, Macías M, Pascasio JM, Moreno JM, Serra MÁ, Arenas J, Real Y, Jorquera F, Calleja JL; Spanish Collaborative Group for the Study of the Use of Hepatitis C Direct-Acting Drugs. Perelló C, et al. J Viral Hepat. 2017 Mar;24(3):226-237. doi: 10.1111/jvh.12637. Epub 2016 Dec 15. J Viral Hepat. 2017. PMID: 27976491
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-Samaniego J, Sacristán B, García-Eliz M, Llerena S, Pascasio JM, Turnes J, Torras X, Morillas RM, Llaneras J, Serra MA, Diago M, Rodriguez CF, Ampuero J, Jorquera F, Simon MA, Arenas J, Navascues CA, Bañares R, Muñoz R, Albillos A, Mariño Z; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Calleja JL, et al. Among authors: ampuero j. J Hepatol. 2017 Jun;66(6):1138-1148. doi: 10.1016/j.jhep.2017.01.028. Epub 2017 Feb 9. J Hepatol. 2017. PMID: 28189751
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
Crespo J, Calleja JL, Fernández I, Sacristan B, Ruiz-Antorán B, Ampuero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M, Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J, Sáez-Royuela F, Arenas J, Rincón D, Prieto M, Jorquera F, Sanchez Ruano JJ, Navascués CA, Molina E, Moya AG, Moreno-Planas JM; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Crespo J, et al. Among authors: ampuero j. Clin Gastroenterol Hepatol. 2017 Jun;15(6):945-949.e1. doi: 10.1016/j.cgh.2017.02.020. Epub 2017 Feb 24. Clin Gastroenterol Hepatol. 2017. PMID: 28238958
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C.
Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernández M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas Á, Figueruela B, Forns X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmerón J, Romero-Gómez M. Ampuero J, et al. J Hepatol. 2018 May;68(5):940-948. doi: 10.1016/j.jhep.2017.12.019. Epub 2017 Dec 28. J Hepatol. 2018. PMID: 29288753
Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry.
Medina-Caliz I, Garcia-Cortes M, Gonzalez-Jimenez A, Cabello MR, Robles-Diaz M, Sanabria-Cabrera J, Sanjuan-Jimenez R, Ortega-Alonso A, García-Muñoz B, Moreno I, Jimenez-Perez M, Fernandez MC, Ginés P, Prieto M, Conde I, Hallal H, Soriano G, Roman E, Castiella A, Blanco-Reina E, Montes MR, Quiros-Cano M, Martin-Reyes F, Lucena MI, Andrade RJ; Spanish DILI Registry. Medina-Caliz I, et al. Clin Gastroenterol Hepatol. 2018 Sep;16(9):1495-1502. doi: 10.1016/j.cgh.2017.12.051. Epub 2018 Jan 4. Clin Gastroenterol Hepatol. 2018. PMID: 29307848
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.
Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, Pareja MJ, Vilar-Gómez E, Caballería J, Escudero-García D, Gomez-Camarero J, Calleja JL, Latorre M, Albillos A, Salmeron J, Aspichueta P, Lo Iacono O, Francés R, Benlloch S, Fernández-Rodríguez C, García-Samaniego J, Estévez P, Andrade RJ, Turnes J, Romero-Gómez M; HEPAmet Registry. Ampuero J, et al. Aliment Pharmacol Ther. 2018 Dec;48(11-12):1260-1270. doi: 10.1111/apt.15015. Epub 2018 Oct 23. Aliment Pharmacol Ther. 2018. PMID: 30353552
231 results